Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer. It is marketed in the US by AstraZeneca under brand Lynparza.
Cedars-Sinai Cancer Center researchers confirmed in a large-scale nationwide survey that pancreatic cancer rates are growing and rising faster among younger women, than males of the same age. Their findings were published in the peer-reviewed journal Gastroenterology.
Although it has long been believed that the microRNA (miRNA) molecules found in pancreatic islets play significant roles in type 2 diabetes, no specific miRNAs have been definitively linked to the condition in humans.
In Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.
The source of tumour cell resistance to immunotherapy was identified by a recent study that examined the pancreatic cancer tumour microenvironment, and novel therapeutic approaches were developed as a result.
In the Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.
A molecular mechanism important for the development of pancreatic cancers has been found by researchers at the University of California, San Diego School of Medicine. The mechanism could possibly contribute to the disease's great resistance to treatment and proclivity for metastasis.
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells.
A randomised clinical trial has found that treating pancreatic cancer patients with chemotherapy before surgery significantly improved 1-year survival rates compared to immediate surgery.
Cancer-causing gene mutation KRAS, found in nearly 30 per cent of all human tumours, successfully shrunk tumours or stopped cancer growth in preclinical models of pancreatic cancer.